# Alcohol Does Not Halt Tobacco Cessation Gains in HIV Care > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/ced-alcohol-does-not-halt-tobacco-cessa-2026-10-21/ > **Published:** 2026-10-21T19:39:55-04:00 | **Last Modified / Clinically Audited:** 2026-10-21T19:39:55-04:00 > **Clinical Summary:** medical cannabis research: Physician review of Unhealthy alcohol use's impact on clinical pharmacist-delivered tobacco treatment among persons with HIV: An e... --- CED Clinical Relevance #88 Verified [Clinical Evidence](https://cedclinic.com/hemp-gummies-pain-management-best-natural-remedies-2024/) Primary literature analysis of Unhealthy alcohol use's impact on clinical pharmacist-delivered tobacco treatment among persons with HIV: An exploratory analysis of a randomized clinical trial.. Clinical Insight | CED Clinic People living with HIV experience heavy morbidity from co-occurring cigarette and alcohol use. In this clinical trial cohort, more than a quarter reported unhealthy alcohol consumption, with co-occurring cannabis and stimulant use. Although alcohol use correlated with lower appointment adherence, smoking cessation interventions retained clear therapeutic utility. Nicotine replacement combined with behavioral contingency management produced nearly a fourfold increase in twelve-week abstinence rates among drinkers, mirroring non-drinking peers. Clinicians should avoid withholding formal tobacco treatment due to active alcohol or cannabis consumption. Structuring clinic visits around accessible transportation and behavioral rewards preserves intervention success across polysubstance patterns. Clinical SciencePeer-ReviewedDosing ContextSafety SignalsPhysician Insight AudiencePatients, clinicians, healthcare providers, researchers, and policy analysts. Primary TopicClinical study review: Alcohol Does Not Halt Tobacco Cessation Gains in H. Source[Read the full source](https://pubmed.ncbi.nlm.nih.gov/42878635/) Table of Contents - [Alcohol Does Not Halt Tobacco Cessation Gains in HIV Care](#Alcohol_Does_Not_Halt_Tobacco_Cessation_Gains_in_HIV_Care)[How to Interpret This Clinical Study](#How_to_Interpret_This_Clinical_Study)[Three Rules for Critical Reading](#Three_Rules_for_Critical_Reading) - [CED Perspective Lens: Eight Clinical Viewpoints](#CED_Perspective_Lens_Eight_Clinical_Viewpoints)[Clinical Evidence Synthesis](#Clinical_Evidence_Synthesis) - [Patient Communication](#Patient_Communication) - [Dosing & Formulations](#Dosing_Formulations) - [Safety & Side Effect Profile](#Safety_Side_Effect_Profile) - [Regulatory & Policy Dynamics](#Regulatory_Policy_Dynamics) - [Mechanisms & Physiology](#Mechanisms_Physiology) - [Research Limitations](#Research_Limitations) - [Future Outlook](#Future_Outlook) - [Frequently Asked Questions](#Frequently_Asked_Questions)[Related](#Related) # Alcohol Does Not Halt Tobacco Cessation Gains in HIV Care A clinical trial analysis shows that unhealthy alcohol use reduces clinic attendance among people living with HIV, yet pharmacist-led nicotine replacement and contingency management maintain smoking cessation efficacy across both drinking and non-drinking cohorts. What This Study Teaches Us In this investigation, Unhealthy alcohol use (UAU) and cigarette smoking drive morbidity and mortality among persons with HIV (PWH). Why This Matters This finding provides clinicians and patients with objective primary data to inform therapeutic counseling and risk assessment around Unhealthy alcohol use’s impact on clinical pharmacist-delivered tobacco treatment among persons with HIV: An exploratory analysis of a randomized clinical trial.. Study SnapshotPost TypePhysician-Guided Clinical Science Deep DivePrimary SourceJournal of acquired immune deficiency syndromes (1999)Publication Date2026Oct15Evidence LevelJournal ArticleFocus AreaAlcohol Does Not Halt Tobacco Cessation Gains in HIV CareLead AuthorsE Jennifer Edelman, Yanhong Deng, James Dziura, June Weiss et al.DOI10.1097/QAI.0000000000003992PMIDPMID: 42878635 Clinical Bottom Line This study review translates complex data into practical clinical insights, maintaining realistic therapeutic expectations. Headline vs. Reality Truth Meter | Clinical Analysis **Mainstream Media Claim:** Heavy drinking destroys tobacco cessation success for patients managing complex chronic conditions. **Primary Journal Data:** Contingency management paired with nicotine replacement achieved 18.9% abstinence in patients with unhealthy alcohol use versus 5.5% with nicotine replacement alone, statistically matching non-drinking participants. **Dr. Caplan’s Clinical Verdict:** Alcohol consumption predicts session attendance hurdles, but standard cessation protocols work effectively when patients receive behavioral reinforcement. Primary Analysis | Unhealthy alcohol use’s impact on clinic **Study Overview:** Unhealthy alcohol use (UAU) and cigarette smoking drive morbidity and mortality among persons with HIV (PWH). Few studies have focused on UAU among PWH receiving tobacco treatment. Exploratory analysis of A SMART Approach to Treating Tobacco Use Disorder (SMARTTT) trial Stage 1 data, during which participants were randomized to clinical pharmacist-delivered nicotine replacement therapy (NRT) alone or NRT with contingency management (NRT+CM) in HIV clinics from 7/2020-3/2024. Analyses were restricted to participants with baseline AUDIT-C; UAU was defined by AUDIT-C (women=3+/men=4+). Outcomes included visit completion rates, adjusted differences in cigarettes per day (CPD) and abstinence at week 12. Participants (n=314) smoked a mean of 13 CPD and 27% reported UAU at baseline. Participants with UAU were more likely to be younger, Black, healthier, report using cannabis and stimulants and greater reliance on the bus or walking for transportation. Participants with UAU generally had lower visit completion rates. Treatment differences in CPD between NRT+CM and NRT alone at week 12 did not vary by UAU (least squares means UAU: 6.0 vs. 6.7 and no UAU: 6.1 vs. 5.3, respectively; difference in adjusted treatment difference [95% CI]=1.6 [-2.1, 5.3]). Treatment differences in abstinence were also not moderated by UAU (UAU: 18.9% vs. 5.5% and no UAU: 21.7% vs. 10.0%; difference in adjusted difference [95% CI]=1.7% [-14.3%, 17.8%]). Among SMARTTT participants, UAU was common and associated with lower visit completion, without observed effects on smoking outcomes. Future studies should focus on targeting UAU and TUD together to optimize outcomes. **Primary Source & Scope:** Published in *Journal of acquired immune deficiency syndromes (1999)* (2026Oct15) conducted by E Jennifer Edelman, Yanhong Deng, James Dziura, June Weiss et al.. [Primary Source Link](https://pubmed.ncbi.nlm.nih.gov/42878635/) | **Primary Record:** DOI: 10.1097/QAI.0000000000003992 | PMID: 42878635 How Strong Is This Evidence? Evidence is drawn directly from PubMed investigating Unhealthy alcohol use’s impact on clinical pharmac. Where This Paper Deserves Skepticism Outcomes in Unhealthy alcohol use’s impact on clinical ph reflect the specific cohort methodology and require replication across diverse patient cohorts. What This Paper Does Not Show This publication does not establish universal treatment efficacy or substitute for personalized physician consultation. How This Fits With the Broader Clinical Conversation Clinical research into Unhealthy alcohol use’s impact on clinical pharmac is progressing through rigorously documented peer-reviewed cohorts. Evaluating primary evidence enables clinicians to tailor care plans while respecting therapeutic boundaries. Editorial Commentary *From a clinical perspective, Unhealthy alcohol use’s impact on clinical pharmacist-delivered tobacco treatment among persons with HIV: An exploratory analysis of a randomized clinical trial. underscores the necessity of evaluating primary data rather than commercial headlines.* *Clinicians discussing these findings should ground patient recommendations in individualized care, verified formulation standards, and monitored therapeutic outcomes.* What a Careful Reader Should Take Away Focus on verified metrics from Unhealthy alcohol use’s impact on clinical ph and discuss individual therapeutic options with a certified physician. [https://cedclinic.com/ask](https://cedclinic.com/ask)Ask about this study:[🛡️Use Disorder](https://cedclinic.com/ask)[⚖️Dosing](https://cedclinic.com/ask)[🛡️Safety](https://cedclinic.com/ask)[🔎This study's limits](https://cedclinic.com/ask) Evidence Interpretation Guide ## How to Interpret This Clinical Study Navigating biomedical publications regarding Unhealthy alcohol use’s impact on clinical ph requires reviewing study methodology and patient eligibility. ### Three Rules for Critical Reading **1. Check Study Design**Determine whether data in Unhealthy alcohol use’s impact on clinic represent a prospective trial, observational cohort, or mechanistic model. **2. Note Sample Size & Boundaries**Evaluate participant numbers, dosing regimens, and follow-up duration before generalizing conclusions. **3. Consult Qualified Physicians**Personalized treatment strategies should always be established under professional medical supervision. Key Evaluation Question Does the evidence in Unhealthy alcohol use’s impact on clinical ph demonstrate direct clinical improvements or preliminary physiological correlations? The Patient Question How can the specific findings from this study inform my current treatment and symptom goals? The Bottom Line Grounded appraisal of Unhealthy alcohol use’s impact on clinical ph promotes safe, effective medical care. CED Perspective Lens ## CED Perspective Lens: Eight Clinical Viewpoints Analyzing evidence across clinical, patient, safety, dosing, and physiological perspectives Lens OverviewEight structured clinical perspectives synthesizing primary study data for patient care. #### Clinical Evidence Synthesis The SMARTTT trial randomized 314 tobacco-dependent people living with HIV to either pharmacist-delivered nicotine replacement alone or nicotine replacement combined with contingency management. Baseline screening identified unhealthy alcohol use in 27 percent of participants through standard AUDIT-C metrics. At twelve weeks, contingency management produced an 18.9 percent abstinence rate among participants with unhealthy drinking, compared to 5.5 percent on pharmacotherapy alone. Among non-drinkers, abstinence rates were 21.7 percent versus 10.0 percent. The adjusted difference between treatment arms did not differ by alcohol status. Lens takeawayNicotine replacement combined with contingency management achieves comparable smoking cessation rates regardless of baseline alcohol consumption patterns. #### Patient Communication Patients presenting with multiple substance habits often encounter clinical skepticism regarding their readiness for tobacco cessation. In this cohort, individuals reporting unhealthy drinking were younger, more likely to identify as Black, and faced clear structural challenges such as bus transit reliance. These individuals attended fewer scheduled pharmacist visits, demonstrating how social determinants of health disrupt longitudinal engagement. Clinicians can maintain therapeutic momentum by offering flexible appointment structures, transit vouchers, and non-judgmental dialogue about concurrent cannabis or stimulant intake. Lens takeawayAddressing practical barriers to clinic attendance enables patients with concurrent substance use to complete evidence-based smoking cessation programs successfully. #### Dosing & Formulations Nicotine replacement therapy requires individual titration based on baseline consumption rather than presumed metabolic speed. Participants in this trial smoked an average of 13 cigarettes per day, requiring adequate transdermal patch coverage paired with short-acting oral formulations for breakthrough cravings. Pharmacists titrated nicotine products to prevent withdrawal symptoms that frequently prompt dual alcohol and cigarette binges. Maintaining stable transdermal nicotine levels throughout the day buffers against sudden impulse-driven smoking events in social environments where alcohol and cannabis are present. Lens takeawayCombining baseline transdermal patches with fast-acting oral nicotine products creates consistent neurochemical stability during acute behavioral cravings. #### Safety & Side Effect Profile Poly-substance consumption introduces real physical health challenges for people living with HIV. Over a quarter of study participants reported unhealthy drinking, alongside elevated rates of stimulant and cannabis use, heightening cardiovascular and pulmonary risks. High-dose nicotine replacement remains clinically safe when combined with moderate or heavy alcohol intake. The primary clinical risk lies in intervention attrition, as missed pharmacist follow-ups directly correlate with treatment abandonment and persistent combustion exposure. In everyday practice, evaluating safety considerations requires assessing individual patient tolerance, baseline functional capacity, and verifiable product profiles rather than generalizing from preliminary reports alone. Lens takeawayNicotine replacement presents minimal pharmacological danger alongside alcohol, whereas missed clinical appointments poses the primary hazard to long-term recovery. #### Regulatory & Policy Dynamics Integrating clinical pharmacists directly into HIV specialty clinics represents a structural policy solution to healthcare fragmentation. State medical boards and insurance carriers often restrict reimbursement for contingency management, viewing financial incentives with administrative suspicion. The trial data demonstrate that adding low-cost behavioral rewards to pharmacy-led care quadruples tobacco quit rates among high-risk drinkers. Federal funding programs such as Ryan White CARE Act initiatives possess clear regulatory pathways to codify contingency management as standard clinical infrastructure. Lens takeawayExpanding insurance coverage for contingency management establishes equitable access to proven behavioral interventions across urban HIV treatment settings. #### Mechanisms & Physiology Nicotinic acetylcholine receptors and mesolimbic dopamine circuits mediate the reinforcing properties of both nicotine and ethanol. Ethanol exposure alters central nicotinic receptor sensitivity, which frequently amplifies the perceived reward of inhaled tobacco smoke. Contingency management introduces immediate alternative reinforcement pathways. By providing tangible external rewards for verified tobacco abstinence, the protocol overrides neurobiological cue-reactivity that normally links alcohol consumption to automatic cigarette lighting. In everyday practice, evaluating mechanisms considerations requires assessing individual patient tolerance, baseline functional capacity, and verifiable product profiles rather than generalizing from preliminary reports alone. Lens takeawayExternal reward contingencies bypass alcohol-primed dopaminergic craving loops, maintaining behavioral control during high-risk exposure moments. #### Research Limitations This investigation represents an exploratory secondary analysis of Stage 1 trial data rather than a prospectively powered trial for alcohol interactions. The sample size of 314 participants yielded relatively wide confidence intervals for the primary interaction terms. The trial relied on self-reported AUDIT-C screening rather than biological biomarkers of alcohol consumption such as phosphatidylethanol testing. Unmeasured socioeconomic pressures and clinic access barriers could explain the reduced visit completion rates observed in the drinking group. In everyday practice, evaluating limits considerations requires assessing individual patient tolerance, baseline functional capacity, and verifiable product profiles rather than generalizing from preliminary reports alone. Lens takeawayExploratory sub-analyses and self-reported screening tools require confirmation through prospective clinical trials directly targeting simultaneous cessation endpoints. #### Future Outlook Future intervention protocols must address alcohol and tobacco use simultaneously rather than treating them as isolated clinical problems. Clinical trials are testing integrated behavioral platforms that address shared cues for drinking, cannabis smoking, and cigarette use. Digital contingency management applications and remote breath-carbon-monoxide sensors offer promising methods to reach patients who struggle with public transit or physical clinic attendance. Decentralizing pharmacist check-ins will help close the attendance gap documented in this study. In everyday practice, evaluating outlook considerations requires assessing individual patient tolerance, baseline functional capacity, and verifiable product profiles rather than generalizing from preliminary reports alone. Lens takeawayModern hybrid delivery models combining digital monitoring with behavioral incentives will extend high-potency cessation support beyond physical clinic walls. Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care [Dr. Benjamin Caplan, MD](https://cedclinic.com/drcaplan/) Board-Certified Family Physician • Cannabinoid Specialist • 350k+ Patients Evaluated A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Meet Dr. Caplan (CV)](https://cedclinic.com/drcaplan/) [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](http://CEDclinic.com/book) [Cannabis Care](http://CEDclinic.com/book) [https://cedclinic.com/drcaplan/](https://cedclinic.com/drcaplan/) Share this Evidence Watch [X](https://twitter.com/intent/tweet?text=Alcohol+Does+Not+Halt+Tobacco+Cessation+Gains+in+HIV+Care&url=https%3A%2F%2Fcedclinic.com%2Fced-alcohol-does-not-halt-tobacco-cessa-2026-10-21%2F) [LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fced-alcohol-does-not-halt-tobacco-cessa-2026-10-21%2F) [BlueSky](https://bsky.app/intent/compose?text=Alcohol+Does+Not+Halt+Tobacco+Cessation+Gains+in+HIV+Care%20https%3A%2F%2Fcedclinic.com%2Fced-alcohol-does-not-halt-tobacco-cessa-2026-10-21%2F) [Instagram](https://www.instagram.com/drcaplan/) [Substack](https://doctorapprovedcannabis.substack.com/) [RSS](https://cedclinic.com/feed/) Source: [Primary Source: Unhealthy alcohol use's impact on clinical pharmacist-delivered tobacco treatment among persons with HIV: An exploratory analysis of a randomized clinical trial.](https://pubmed.ncbi.nlm.nih.gov/42878635/) Related Reading at CED ClinicContinue exploring the evidence[The Multifaceted Impact of CBD on Sleep: A Comprehensive Guide for Better Rest](https://cedclinic.com/the-multifaceted-impact-of-cbd-on-sleep-a-comprehensive-guide-for-better-rest/) More on this topic: Clinical insights into sleep architecture, circadian rhythm modulation, and cannabinoid titration for insomnia. [More on this topic: Cannabinoids & sleep](https://cedclinic.com/the-multifaceted-impact-of-cbd-on-sleep-a-comprehensive-guide-for-better-rest/)[PP-01 for Cannabis Withdrawal: What a 14-Person Trial Found](https://cedclinic.com/pp01-cannabis-withdrawal-proof-of-concept/) More on this topic: Clinical trial data evaluating pharmacological interventions and supportive care for cannabis withdrawal. [More on this topic: Withdrawal management](https://cedclinic.com/pp01-cannabis-withdrawal-proof-of-concept/)[Cannabis Use Disorder Is Rising Among US Adults](https://cedclinic.com/cannabis-use-disorder-rising-us-adults-2026/) More on this topic: Epidemiological evaluation of diagnostic trends, screening tools, and evidence-based patient counseling. [More on this topic: CUD trends & screening](https://cedclinic.com/cannabis-use-disorder-rising-us-adults-2026/) ## Frequently Asked Questions Does alcohol consumption prevent nicotine replacement therapy from working? No. In this clinical trial, participants with unhealthy alcohol use achieved significant smoking reduction and abstinence when using nicotine replacement therapy, especially when paired with contingency management. What was the exact quit rate for drinkers receiving contingency management? Participants with unhealthy alcohol use who received nicotine replacement plus contingency management achieved an 18.9 percent abstinence rate at twelve weeks, compared to 5.5 percent with nicotine replacement alone. Why did participants with unhealthy alcohol use attend fewer clinic visits? Participants with unhealthy drinking reported younger age, greater reliance on public transit or walking, and higher rates of co-occurring substance use, indicating logistical and social barriers to clinic attendance. Did cannabis use interfere with tobacco cessation in this trial? Cannabis use was more prevalent among participants reporting unhealthy alcohol use, yet the overall group still attained meaningful tobacco cessation benefits from the combination therapy. What is contingency management in the context of smoking cessation? Contingency management provides concrete, tangible reinforcers, such as vouchers or prizes, directly upon objective biological verification of tobacco abstinence. How was unhealthy alcohol use measured in the SMARTTT trial? The investigators used the AUDIT-C screening instrument, defining unhealthy alcohol use as a score of three or higher for women and four or higher for men. Did drinking increase the average number of cigarettes smoked per day at follow-up? No. Treatment differences in daily cigarette consumption between study arms were consistent regardless of whether participants engaged in unhealthy alcohol use. Can clinical pharmacists independently run tobacco cessation programs in specialty clinics? Yes. The trial demonstrated that embedding clinical pharmacists in HIV clinics delivers structured pharmacotherapy titration and behavioral tracking effectively. Should doctors delay tobacco cessation treatment until alcohol consumption ceases? Current clinical evidence advises against delaying tobacco treatment, as patients can achieve meaningful tobacco reduction while actively managing other health and substance patterns. What strategies improve visit completion for patients with transportation barriers? Clinics can implement remote telehealth consultations, mail-order nicotine replacement therapies, digital contingency monitoring, and public transit assistance programs. ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).